How fast will Mounjaro work — and what does 'working' actually look like?

Appetite changes are often the first sign Mounjaro is working, many people notice reduced hunger or earlier fullness within one to two weeks of the starter dose.
The 2.5 mg starting dose exists to let your body adjust, not to produce rapid weight loss; meaningful weight change tends to build as the dose increases.
In the SURMOUNT-1 trial, participants lost an average of around 20–21% of body weight over 72 weeks at the highest dose, steady, gradual loss rather than a sudden drop.
Individual response varies: factors including starting BMI, metabolic health, diet quality and activity level all influence how quickly results appear.

Most people notice Mounjaro's appetite-suppressing effect within the first one to two weeks of starting treatment, though visible weight change typically takes a little longer to show. The timeline isn't the same for everyone — dose, starting weight, diet and individual biology all play a role. Mounjaro (tirzepatide) is a prescription-only medicine; a prescriber assesses whether it's clinically suitable for you before any treatment begins. What follows is a plain account of what the evidence and clinical experience actually suggest, week by week.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Your Mounjaro timeline: what's happening at each stage

Step 1, Weeks 1 to 4: the body adjusting (2.5 mg)

The first pen you use contains the 2.5 mg dose. Its job is adjustment, not transformation. Tirzepatide activates both GIP and GLP-1 receptors in a way that slows gastric emptying and reduces appetite signals, but at 2.5 mg the effect is deliberately modest, the starter dose is calibrated to minimise nausea and give your digestive system time to settle. Some people feel noticeably less hungry within days. Others notice very little. Both are normal.

What you're unlikely to see yet is a significant change on the scales. A small early drop is common (partly reduced food volume, partly water), but this phase is more about tolerability than results. The most common experiences in this window are mild nausea, some bloating, or a subtle sense of feeling full sooner, occasionally all three. These usually ease within a week or two. A useful habit many patients mention: keeping the pen in the fridge door so the weekly injection fits naturally into a Sunday-morning routine rather than becoming something easy to forget.

The NHS patient information for tirzepatide gives a clear account of what to expect and when to speak to a healthcare professional if side effects feel more than mild.

Step 2 (Weeks 4 to 16: the dose increases and results start building

After four weeks at 2.5 mg, your prescriber will typically move you to 5 mg) and this is usually when people start to notice genuine weight change. Appetite suppression becomes more consistent. Meal portions that once felt normal can start to feel like too much. Cravings for high-calorie foods often become easier to ignore.

Weight loss in this phase is real but rarely dramatic week to week. If you're curious about how quickly Mounjaro will work for you, a steady one to two pounds per week is a reasonable ballpark for many people, though slower progress is common and not a sign treatment isn't working. The body's response to a reduced energy intake tends to accelerate as the dose increases toward 7.5 mg and 10 mg. For a fuller picture of typical weight-loss trajectories at different doses, the rate of weight loss on Mounjaro page goes into more detail.

Gastrointestinal side effects (nausea, loose stools, reflux) are most likely to reappear briefly after each dose step, then settle again. Keeping meals smaller and lower in fat during those first few days after a dose change helps most people manage this.

Step 3, Weeks 16 and beyond: reaching a therapeutic dose

At higher doses (10 mg, 12.5 mg and 15 mg), the appetite effect tends to be strongest and weight loss most consistent. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that adults taking 15 mg tirzepatide lost an average of around 20–21% of their body weight over 72 weeks. That figure comes from thousands of participants followed over more than a year, it reflects what sustained, well-supported treatment can achieve, not what happens in the first few weeks. A closer look at the full working timeline for Mounjaro covers the later phases in more depth.

Progress in this phase is rarely a straight line. Weight can plateau for a few weeks, then drop again. This is a recognised pattern, not failure, and not a reason to stop without speaking to your prescriber. NICE's guidance on tirzepatide (TA1026) notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing should be reviewed. That review is a clinical conversation, not an automatic end to treatment.

What affects your personal timeline

No two timelines look identical. Starting BMI matters: people with a higher starting weight often see faster absolute losses early on, while those closer to the eligibility threshold may see smaller numbers but still meaningful health changes. Metabolic health plays a role too, blood glucose regulation, thyroid function, sleep quality and stress all affect how the body responds to a calorie deficit.

Diet and activity aren't just add-ons. Mounjaro is licensed alongside a reduced-calorie diet and increased activity, and the trial results reflect that combination. Keeping protein intake adequate while appetite is suppressed takes conscious effort and matters for preserving muscle alongside fat. For context on what this all costs in practical and financial terms, the Mounjaro cost and value guide is worth a read before starting.

If you're wondering how fast Mounjaro works and how that translates into the speed of effect compared with other GLP-1 medicines, the tirzepatide onset and effect page covers the pharmacology more directly. And if you want to discuss your own starting point with a prescriber, check your eligibility with our clinical team, it's free, and a real prescriber reads every response the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions